CAR-based adoptive cell therapy (ACT) has shown a remarkable ability to treat and occasionally cure cancer by evoking or grafting an anti-cancer immune response into patients with hematological malignancies but has yet to show similar efficacy in solid tumors. In...
Meet us
Nextera at BIO Europe 2023
CEO/CSO Geir Åge Løset and Head of Business Development Francis Yuan will attend the BIO Europe 2023 in Munich, Germany, November 6 – 8. We are interested in discussing partnerships, collaborations, and asset out-licensing - please get in touch if you would like...
Nextera partnering Multi-Functional Cell Therapies Summit, May 4-6
Nextera’s CEO, Geir Åge Løset will give the presentation ” Combinatorial specificity profiling and engineering to safeguard and optimize TCR reactivity”
Nextera invited to PEGS Europe.
At the 12th annual PEGS Europe Summit, Nextera’s CEO GeirÅge Løset will present Nextera’s NextCore drug discovery platform.
Nextera presents at Antibody Engineering & Therapeutics, Europe VIRTUAL, 24-27th August
This conference is the industry’s event for antibody and protein therapeutic science and technology in Europe. Nextera is in the forefront of such technology development.
Nextera joins the BIO International Convention
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO International Convention June 8th – 12th. Book us for a digital meeting and we will present our unique NextCore Immunology platform.
Nextera Attending BIO Europe Spring
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO Europe Spring Digital conference March 23rd – 25th.